Lighthouse Investment Partners LLC Invests $2.11 Million in Cencora, Inc. (NYSE:COR)

Lighthouse Investment Partners LLC purchased a new position in shares of Cencora, Inc. (NYSE:COR) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 9,400 shares of the company’s stock, valued at approximately $2,112,000.

Other hedge funds also recently modified their holdings of the company. Czech National Bank boosted its holdings in Cencora by 7.0% in the 4th quarter. Czech National Bank now owns 38,025 shares of the company’s stock valued at $8,543,000 after purchasing an additional 2,489 shares during the period. Trust Co. of Toledo NA OH boosted its holdings in Cencora by 32.6% in the 4th quarter. Trust Co. of Toledo NA OH now owns 1,358 shares of the company’s stock valued at $305,000 after purchasing an additional 334 shares during the period. City State Bank boosted its holdings in Cencora by 19.3% in the 4th quarter. City State Bank now owns 618 shares of the company’s stock valued at $139,000 after purchasing an additional 100 shares during the period. Wedmont Private Capital boosted its holdings in Cencora by 33.1% in the 4th quarter. Wedmont Private Capital now owns 2,453 shares of the company’s stock valued at $579,000 after purchasing an additional 610 shares during the period. Finally, Cooper Financial Group lifted its holdings in shares of Cencora by 8.1% during the 4th quarter. Cooper Financial Group now owns 3,211 shares of the company’s stock worth $721,000 after acquiring an additional 240 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on COR. Bank of America raised their price objective on shares of Cencora from $270.00 to $285.00 and gave the stock a “neutral” rating in a report on Friday, April 11th. Evercore ISI raised their price objective on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. UBS Group increased their target price on shares of Cencora from $298.00 to $335.00 and gave the stock a “buy” rating in a research report on Tuesday, April 29th. Morgan Stanley set a $288.00 target price on shares of Cencora in a research report on Tuesday, April 15th. Finally, Robert W. Baird increased their target price on shares of Cencora from $314.00 to $350.00 and gave the stock an “outperform” rating in a research report on Thursday, May 8th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $301.18.

Cencora Trading Up 0.2%

COR opened at $279.00 on Wednesday. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The stock has a market capitalization of $54.10 billion, a PE ratio of 39.69, a PEG ratio of 1.31 and a beta of 0.60. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $309.35. The firm has a 50-day moving average price of $277.02 and a two-hundred day moving average price of $253.87.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating the consensus estimate of $4.07 by $0.35. The firm had revenue of $75.50 billion during the quarter, compared to analysts’ expectations of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company posted $3.80 EPS. As a group, equities analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 2nd. Stockholders of record on Friday, May 16th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.79%. The ex-dividend date of this dividend is Friday, May 16th. Cencora’s dividend payout ratio (DPR) is presently 25.52%.

Insider Activity

In other news, EVP Silvana Battaglia sold 5,000 shares of the firm’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the transaction, the executive vice president now owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. This trade represents a 24.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the firm’s stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the completion of the transaction, the executive vice president now directly owns 14,665 shares in the company, valued at $3,934,326.20. This trade represents a 21.96% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,223 shares of company stock valued at $13,580,967. 10.80% of the stock is currently owned by insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.